Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncolog...
26 April 2018 - 3:06AM
Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced
that new interim results from the Company’s ongoing Phase 2a study
of cerdulatinib in patients with Non-Hodgkin Lymphoma (NHL),
including B-cell NHL and relapsed/refractory peripheral T-cell
lymphoma (PTCL), will be presented during a Poster Discussion
Session at the 2018 American Society of Clinical Oncology (ASCO)
Annual Meeting, June 1-5, in Chicago.
Cerdulatinib is an investigational oral, dual
SYK/JAK kinase inhibitor that uniquely inhibits two key cell
signaling pathways that promote cancer cell growth in certain
hematologic malignancies. It is being developed for the treatment
of resistant or relapsed hematologic cancer.
Poster Presentation Details:
- Presentation Title: The Dual SYK/JAK Inhibitor
Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study
in Patients with Relapsed/Refractory B- and T-Cell Non-Hodgkin
Lymphoma (NHL)
- Presenter: Paul A. Hamlin, M.D., Memorial
Sloan Kettering Cancer Center
- Abstract Number: 7511
- Poster Board: 148
- Session Title: Hematologic Malignancies –
Lymphoma and Chronic Lymphocytic Leukemia
- Date and Time: Monday, June 4, 2018 from 1:15
p.m. – 2:30 p.m. CT
- Location: E450, McCormick Place
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company’s
first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa
inhibitor, was approved by the U.S. Food and Drug Administration in
June 2017. The company is also working to advance two clinical
programs for andexanet alfa, a recombinant protein designed to
reverse the anticoagulant effect in patients treated with an oral
or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK
inhibitor in development to treat hematologic cancers. Portola's
partnered program is focused on developing selective SYK inhibitors
for inflammatory conditions. For more information, visit
http://www.portola.com and follow the Company on Twitter
@Portola_Pharma.
Investor
Contact: |
Media
Contact: |
Cara Miller |
Laurie Masonson |
Portola
Pharmaceuticals |
Pure
Communications |
ir@portola.com |
lmasonson@purecommunications.com |
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Apr 2024 to May 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles